Moody National Bank Trust Division Cuts Stock Position in Insulet Co. (NASDAQ:PODD)

Moody National Bank Trust Division lessened its stake in shares of Insulet Co. (NASDAQ:PODDGet Rating) by 55.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,787 shares of the medical instruments supplier’s stock after selling 3,475 shares during the quarter. Moody National Bank Trust Division’s holdings in Insulet were worth $607,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PODD. Dimensional Fund Advisors LP grew its holdings in Insulet by 1.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 95,158 shares of the medical instruments supplier’s stock worth $25,320,000 after acquiring an additional 1,809 shares during the period. HighTower Advisors LLC grew its holdings in Insulet by 32.0% during the fourth quarter. HighTower Advisors LLC now owns 1,683 shares of the medical instruments supplier’s stock worth $457,000 after acquiring an additional 408 shares during the period. Rhumbline Advisers grew its holdings in Insulet by 2.1% during the fourth quarter. Rhumbline Advisers now owns 71,528 shares of the medical instruments supplier’s stock worth $19,031,000 after acquiring an additional 1,504 shares during the period. Ensign Peak Advisors Inc grew its holdings in Insulet by 115.1% during the fourth quarter. Ensign Peak Advisors Inc now owns 41,338 shares of the medical instruments supplier’s stock worth $10,999,000 after acquiring an additional 22,117 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in Insulet by 2.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 370,097 shares of the medical instruments supplier’s stock worth $98,473,000 after acquiring an additional 8,201 shares during the period.

Analyst Ratings Changes

A number of research analysts recently weighed in on PODD shares. Raymond James upped their price objective on Insulet from $262.00 to $280.00 in a report on Friday, August 5th. Canaccord Genuity Group upped their target price on Insulet from $250.00 to $290.00 and gave the company a “buy” rating in a report on Friday, August 5th. Piper Sandler upped their target price on Insulet from $230.00 to $235.00 and gave the company a “neutral” rating in a report on Friday, August 5th. BTIG Research upped their target price on Insulet to $285.00 in a report on Tuesday, August 9th. Finally, Robert W. Baird upped their target price on Insulet from $245.00 to $300.00 and gave the company an “outperform” rating in a report on Friday, August 5th. One analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $295.23.

Insulet Stock Down 1.6 %

PODD opened at $255.00 on Monday. The company has a quick ratio of 3.54, a current ratio of 4.69 and a debt-to-equity ratio of 3.28. The firm has a market cap of $17.70 billion, a P/E ratio of 510.00 and a beta of 0.73. Insulet Co. has a 52 week low of $181.00 and a 52 week high of $324.81. The business’s fifty day simple moving average is $254.61 and its 200 day simple moving average is $240.26.

Insulet (NASDAQ:PODDGet Rating) last released its earnings results on Thursday, August 4th. The medical instruments supplier reported ($0.50) earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.72). Insulet had a return on equity of 13.83% and a net margin of 2.94%. The business had revenue of $299.40 million for the quarter, compared to analysts’ expectations of $290.87 million. During the same quarter last year, the company posted $0.10 earnings per share. The business’s quarterly revenue was up 13.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Insulet Co. will post 0.76 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Bret Christensen sold 2,900 shares of the stock in a transaction dated Wednesday, August 24th. The stock was sold at an average price of $264.24, for a total transaction of $766,296.00. Following the transaction, the executive vice president now directly owns 19,551 shares in the company, valued at $5,166,156.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Shacey Petrovic sold 15,000 shares of the firm’s stock in a transaction dated Friday, July 1st. The stock was sold at an average price of $222.90, for a total value of $3,343,500.00. Following the transaction, the director now directly owns 13,695 shares in the company, valued at approximately $3,052,615.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Bret Christensen sold 2,900 shares of the firm’s stock in a transaction dated Wednesday, August 24th. The stock was sold at an average price of $264.24, for a total value of $766,296.00. Following the completion of the transaction, the executive vice president now owns 19,551 shares in the company, valued at $5,166,156.24. The disclosure for this sale can be found here. 0.90% of the stock is currently owned by company insiders.

Insulet Company Profile

(Get Rating)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.

Read More

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODDGet Rating).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.